The results of your experiment are listed in the table:Initial velocity measurements (mAbs/s)CENTA concentration(µM)[NSAMB) = 0 nM[NSAMB] = 20 nM[NSAMB] = 40 nM[NSAMB] = 80 nM150.1250.1020.0870.066300.1670.1450.1290.105600.2000.1840.1700.1481200.2220.2120.2020.1862400.2350.2290.2240.213 You have determined the mode of inhibition for NSAMB but you must now determine the KI value to obtain a relative measure of the potency of this inhibitor.Based on the mode of inhibition, how are the equations for KP and V influenced by the presence of inhibitor?rappVmasK is unaffected by changes in [I]; VpPmax1+KMVappmax1+1+KIKPPКм(1+ )Vappmax=MK11+Neither KPP nor VPPappmax are affected by changes in IO KP = KM(1+ *): V is unaffected by changes in [I]appM

Km app and Vmax app are the km and Vmax of the enzyme in the presence of inhibitor. Depending on the…

Answered: You have determined the mode of…

Curren'S Math For Meds: Dosages & Sol

11th Edition

ISBN:9781305143531

Author:CURREN

Publisher:CURREN

Chapter16: Adult And Pediatric Dosages Based On Body Surface Area

Section: Chapter Questions

Problem 5.4P

See similar textbooks

Similar questions

Based on your Lineweaver-Burk plot, what is the mode of PaESBL-1 inhibition by NSAMB? What is the equation for the double-reciprocal plot at 20 nMnM NAMB?
Which ONE of these statements is the most accurate definition of the mode of action of imatinib? Select one: A.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks phosphatase activity by competing with adenosine triphosphate (ATP) binding B.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks tyrosine kinase activity by competing with adenosine triphosphate (ATP) binding C.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks tyrosine kinase activity by interaction with the enzyme site D.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks phosphatase activity by interaction with the enzyme site
During an SAR effort to identify tyrosine kinase inhibitors, it was found that compound 2 was significantly more potent and selective than compound 1. To what might you attribute this improvement in activity and selectivity? Explain. IC-5 micromolar IC-0.1 mromolar
From the Hill Plot below, the of the first binding event for the receptor-ligand system under study is: Q1 4 nM 10 μΜ -2 nM 2 nM Calculate the Hill Coefficient from the receptor-ligand binding data below: Q2 4 100 2 3 (077) log 10 8 6 4 2 0 -2 -4 -6 -6 -4 -2 0 2 4 log [L] (nM) 6 8 10
Based on the principles of RP-HPLC, which sub fraction in the figure (P1 to P8) is the most polar? Explain.
added ligand concentration of 10 µM is 5 × 10³ s¹. What is the value of the reverse rate constant k_1 = 1 ×10-4 Incorrect Macmillan Learning You have not correctly calculated the value of the reverse rate constant. To begin, calculate the value of k₁ by dividing the rate of receptor-ligand complex formation (the rate of the forward reaction) by the ligand concentration. k₁ = rate forward [L] Then, calculate the value of the reverse rate constant, k_₁, by multiplying the dissociation constant, Kd, and the forward rate constant, k₁. k_1 = Kak₁
CTP inhibits ATCase; however, the inhibition is not complete. Can you suggest another molecule that might enhance the inhibition of ATCase?
Using the information given, determine the Kd for the binding of HABA to BSA. B= y-intercept (E bound) 2457.6x (E unbound) Data for the binding of HABA to BSA y = 4E-06x + 5.2134 R² = 0.928
CYP2E1 has a much higher Km for ethanol than ADH (11 mM versus 0.05 mM,respectively). When greater portions of ethanol are ingested (0.08% or 17 mM), which part of the statement would be true?
Functional and structural analysis indicates that Gleevec is an ATPcompetitive inhibitor of the Bcr-Abl kinase. In fact, many kinase inhibitors under investigation or currently marketed as drugs are ATP competitive. Can you suggest a potential drawback of drugs that utilize this particular mechanism of action?
Why does the apparent KM decrease in the presence ofan uncompetitive inhibitor?
Two GPCR mutations (Mutant A and Mutant B) were tested for activity. One was confirmed as being a constitutively activating, gain of function GPCR mutation and one was confirmed as being a loss of function GPCR mutation. Which is which? Explain your answer.

SEE MORE QUESTIONS

Recommended textbooks for you

Curren'S Math For Meds: Dosages & Sol

Nursing

ISBN:

9781305143531

Author:

CURREN

Publisher:

Cengage

Curren'S Math For Meds: Dosages & Sol

Nursing

ISBN:

9781305143531

Author:

CURREN

Publisher:

Cengage

SEE MORE TEXTBOOKS